Cynosure Inc. (CYNO) VP Douglas J. Delaney Sells 7,875 Shares
Cynosure Inc. (NASDAQ:CYNO) VP Douglas J. Delaney sold 7,875 shares of the firm’s stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $45.00, for a total value of $354,375.00. Following the sale, the vice president now directly owns 5,833 shares in the company, valued at $262,485. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Cynosure Inc. (NASDAQ:CYNO) traded up 0.56% on Tuesday, reaching $45.25. The company had a trading volume of 480,526 shares. Cynosure Inc. has a 1-year low of $32.90 and a 1-year high of $55.94. The firm has a market capitalization of $1.08 billion, a P/E ratio of 51.13 and a beta of 1.71. The company’s 50-day moving average price is $46.27 and its 200 day moving average price is $49.49.
Cynosure (NASDAQ:CYNO) last issued its quarterly earnings data on Tuesday, October 25th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. The business earned $106.40 million during the quarter, compared to the consensus estimate of $101.11 million. Cynosure had a net margin of 4.97% and a return on equity of 6.82%. The company’s revenue was up 35.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.21 earnings per share. On average, equities analysts forecast that Cynosure Inc. will post $1.28 EPS for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CYNO. Quantitative Systematic Strategies LLC bought a new position in Cynosure during the third quarter valued at $248,000. Cornerstone Capital Management Holdings LLC. increased its position in Cynosure by 73.1% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 109,162 shares of the company’s stock valued at $5,560,000 after buying an additional 46,101 shares during the period. Jane Street Group LLC bought a new position in Cynosure during the third quarter valued at $253,000. Panagora Asset Management Inc. increased its position in Cynosure by 68.0% in the third quarter. Panagora Asset Management Inc. now owns 24,959 shares of the company’s stock valued at $1,271,000 after buying an additional 10,099 shares during the period. Finally, Highbridge Capital Management LLC bought a new position in Cynosure during the third quarter valued at $201,000. Hedge funds and other institutional investors own 98.49% of the company’s stock.
A number of equities research analysts have commented on the company. Stifel Nicolaus reissued a “buy” rating and set a $58.00 price target (down from $62.00) on shares of Cynosure in a report on Wednesday, October 26th. Zacks Investment Research lowered Cynosure from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 19th. Northcoast Research restated a “buy” rating on shares of Cynosure in a research report on Monday, November 14th. Leerink Swann restated an “outperform” rating and set a $60.00 price objective (down previously from $63.00) on shares of Cynosure in a research report on Friday, October 28th. Finally, Brean Capital restated a “buy” rating and set a $60.00 price objective (up previously from $54.00) on shares of Cynosure in a research report on Thursday, July 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $60.43.
Cynosure Company Profile
Cynosure Inc (Cynosure) develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecologic health.
Receive News & Stock Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related stocks with our FREE daily email newsletter.